Participants 84 162 5
patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98).
Participants 419 538 6
One hundred patients were randomized to receive standard (CDA 0.14 mg/kg/day day 1-5 [Arm A]) or experimental treatment
